Axsome Therapeutics' GAAP loss for 6M 2021 was $61.544 million, up 21.1% from $50.811 million in the prior year.
Axsome Therapeutics' GAAP loss for 6M 2021 was $61.544 million, up 21.1% from $50.811 million in the prior year.
Financial results
Axsome Therapeutics' GAAP loss for 6M 2021 was $61.544 million, up 21.1% from $50.811 million in the prior year. 
axsometherapeuticsinc.gcs-web.com
English (US) 